{
    "data": [
        {
            "id": "4659313",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-22T23:35:19-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441979374/image_1441979374.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Ottava Surgical Robot Is A Growth Tailwind",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106511",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506071",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659313-johnson-and-johnson-ottava-surgical-robot-growth-tailwind"
            }
        },
        {
            "id": "4655948",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-05T00:55:04-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1497108072/image_1497108072.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. Pfizer: Better Pharma Stock?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104695",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "506434",
                            "type": "sentiment"
                        },
                        {
                            "id": "506435",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655948-johnson-and-johnson-vs-pfizer-better-pharma-stock"
            }
        },
        {
            "id": "4655481",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-02T10:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Big Week On Tap For McDonald's, Shopify, GameStop, And Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655481-stocks-to-watch-big-week-on-tap-for-mcdonalds-shopify-gamestop-and-johnson-and-johnson"
            }
        },
        {
            "id": "4655246",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-30T15:11:59-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444415096/image_1444415096.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Sleep Well At Night With The Only AAA-Rated Dividend Aristocrat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505624",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655246-johnson-and-johnson-sleep-well-at-night-with-the-only-aaa-rated-dividend-aristocrat"
            }
        },
        {
            "id": "4654982",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-29T16:48:35-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420930627/image_1420930627.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson, Ben Graham, And Defensive Stocks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505644",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4654982-johnson-and-johnson-ben-graham-and-defensive-stocks"
            }
        },
        {
            "id": "4645279",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-31T05:13:59-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1416811314/image_1416811314.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Johnson & Johnson Stock Worth Buying Following Q3 2023 Earnings?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "497852",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4645279-is-johnson-and-johnson-stock-worth-buying-following-q3-2023-earnings"
            }
        },
        {
            "id": "4644837",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-30T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/665802046/image_665802046.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Litigation Joker In Johnson & Johnson's Deck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "497254",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4644837-the-litigation-joker-in-johnson-and-johnson-deck"
            }
        },
        {
            "id": "4642118",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-20T09:12:09-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324246637/image_1324246637.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Q3 Earnings Unveils Life After Kenvue Spinoff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "494861",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4642118-johnson-and-johnson-q3-earnings-unveils-life-after-kenvue-spinoff"
            }
        },
        {
            "id": "4640209",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-16T07:05:00-04:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1198972656/image_1198972656.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "492647",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640209-johnson-and-johnson-conservative-high-yield-dividend-aristocrat-buy"
            }
        },
        {
            "id": "4640674",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-13T11:56:06-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493320",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640674-johnson-and-johnson-q3-earnings-preview-dont-count-different-proposition-post-kenvue-spin-out"
            }
        },
        {
            "id": "4636898",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-23T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Bull Case Can No Longer Be Ignored",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "488059",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4636898-johnson-and-johnson-the-bull-case-can-no-longer-be-ignored"
            }
        },
        {
            "id": "4635885",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-18T17:46:58-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170408564/image_1170408564.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Very Cautious 'Buy'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486488",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635885-johnson-and-johnson-a-very-cautious-buy"
            }
        },
        {
            "id": "4635728",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-18T07:35:51-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1480096606/image_1480096606.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Reinvention - Is A New Logo Enough?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107118",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486406",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635728-johnson-and-johnson-reinvention-new-logo-enough"
            }
        },
        {
            "id": "4635669",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-18T00:58:39-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225119943/image_1225119943.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Kenvue Spin-Off Unlikely To Drive Market-Beating Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107131",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486345",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635669-johnson-and-johnson-kenvue-spin-off-unlikely-to-drive-market-beating-returns"
            }
        },
        {
            "id": "4635622",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-17T07:02:14-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: AAA-Rated And Potentially 20% Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "92986",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "486302",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4635622-johnson-and-johnson-aaa-rated-and-potentially-20-percent-undervalued"
            }
        },
        {
            "id": "4630884",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-24T13:20:00-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352917067/image_1352917067.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Kenvue Separation Won't Impact Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630884-johnson-and-johnson-kenvue-separation-wont-impact-dividends"
            }
        },
        {
            "id": "4628985",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-17T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481248245/image_1481248245.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. Kenvue: The Better Dividend Aristocrat Might Shock You",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "478686",
                            "type": "sentiment"
                        },
                        {
                            "id": "478687",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4628985-johnson-and-johnson-vs-kenvue-better-dividend-aristocrat-might-shock-you"
            }
        },
        {
            "id": "4628558",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-15T08:45:33-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1480096603/image_1480096603.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Stock: Outlook Amid Lawsuits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "478162",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4628558-johnson-and-johnson-stock-outlook-amid-lawsuits"
            }
        },
        {
            "id": "4625049",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-07T17:44:22-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1042651550/image_1042651550.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Future Prospects For Johnson & Johnson Following Strong Q2 Performance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "476432",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4625049-future-prospects-for-johnson-and-johnson-following-strong-q2-performance"
            }
        },
        {
            "id": "4619210",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-24T12:34:15-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Resilient, But Clarification On Liability Issue Is Needed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472798",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619210-johnson-and-johnson-resilient-but-clarification-on-liability-issue-is-needed"
            }
        },
        {
            "id": "4617846",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-18T12:31:21-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417761158/image_1417761158.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Q2 Earnings Will Satisfy Market, But May Mask Wider Issues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "471571",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617846-johnson-and-johnson-q2-earnings-will-satisfy-market-but-may-mask-wider-issues"
            }
        },
        {
            "id": "4617522",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-17T10:51:59-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405770120/image_1405770120.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Stock Q2 Earnings Preview: News On Kenvue Distribution Expected?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "471196",
                            "type": "sentiment"
                        },
                        {
                            "id": "471197",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617522-johnson-and-johnson-stock-q2-earnings-preview-kenvue-distribution-expected"
            }
        },
        {
            "id": "4615559",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-06T14:48:32-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499085898/image_499085898.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Supplemental BLA Of Carvykti Gives Great Growth Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "463290",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615559-johnson-and-johnson-supplemental-bla-of-carvykti-gives-great-growth-opportunity"
            }
        },
        {
            "id": "4614519",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-29T23:26:48-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Buy The Market (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106871",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "467294",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4614519-johnson-and-johnson-buy-the-market-technical-analysis"
            }
        },
        {
            "id": "4614458",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-29T15:31:03-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Pay Yourself 7% With This Bond-Like Exposure",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106271",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "467226",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4614458-johnson-and-johnson-pay-yourself-7-percent-with-this-bond-like-exposure"
            }
        },
        {
            "id": "4610330",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-08T13:23:45-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Relinquishes Top Spot To Eli Lilly, Shares Undervalued Amid Technical Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462141",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4610330-johnson-and-johnson-relinquishes-top-spot-to-eli-lilly-shares-undervalued-amid-technical-risks"
            }
        },
        {
            "id": "4608141",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-30T06:52:44-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/119562180/image_119562180.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Ultimate Bull Trap Is Here",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "459710",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4608141-johnson-and-johnson-stock-ultimate-bull-trap-here-reiterate-hold"
            }
        },
        {
            "id": "4601865",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-09T06:40:15-04:00",
                "isLockedPro": false,
                "commentCount": 72,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131216270/image_1131216270.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Or Johnson & Johnson? Let's Ask Peter Lynch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454915",
                            "type": "sentiment"
                        },
                        {
                            "id": "454916",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4601865-abbvie-or-johnson-and-johnson-lets-ask-peter-lynch"
            }
        },
        {
            "id": "4601270",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-07T10:28:58-04:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: An Update Following The Kenvue IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454490",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4601270-johnson-and-johnson-an-update-following-the-kenvue-ipo"
            }
        },
        {
            "id": "4598515",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-01T11:59:55-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1480096589/image_1480096589.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Holding Value In Wake Of Lawsuits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103970",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "453222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4598515-johnson-and-johnson-holding-value-in-wake-of-lawsuits"
            }
        },
        {
            "id": "4598090",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-29T10:00:55-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Eyes On Apple, Cloudflare, Canadian National Railway And Berkshire Hathaway",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4598090-stocks-to-watch-eyes-on-apple-cloudflare-canadian-national-railway-and-berkshire-hathaway"
            }
        },
        {
            "id": "4596621",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-26T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Reliable Dividend Of 2.9% With Steady Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106554",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "452129",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4596621-johnson-and-johnson-reliable-dividend-steady-growth"
            }
        },
        {
            "id": "4595136",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-20T00:11:13-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/826767166/image_826767166.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: U.S. Health Trends A Key Catalyst For Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105052",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450793",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4595136-johnson-and-johnson-us-health-trends-key-catalyst-growth"
            }
        },
        {
            "id": "4594810",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-18T17:12:59-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170407683/image_1170407683.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Remains The Blue-Chip Dividend King To Own",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450702",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594810-johnson-and-johnson-remains-the-blue-chip-dividend-king-to-own"
            }
        },
        {
            "id": "4594789",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-18T15:52:33-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Dividend: 61 And Counting",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450610",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594789-johnson-and-johnsons-dividend-61-and-counting"
            }
        },
        {
            "id": "4594559",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-17T15:52:17-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155381041/image_155381041.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: 4 Key Areas Of Focus Ahead Of Q1 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450479",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594559-johnson-and-johnson-q1-earnings-preview-key-areas-of-focus"
            }
        },
        {
            "id": "4594425",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-17T08:30:05-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346156711/image_1346156711.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Q1 Earnings Preview: More Pain Ahead?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "450274",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4594425-johnson-and-johnson-q1-earnings-preview-more-pain-ahead"
            }
        },
        {
            "id": "4594230",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-15T10:00:25-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Eyes On The Health Of Financials, Housing Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594230-stocks-to-watch-eyes-on-the-health-of-financials-housing-sector"
            }
        },
        {
            "id": "4593425",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-11T10:23:52-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Should Comfortably Handle Talc Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449180",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4593425-johnson-and-johnson-should-comfortably-handle-talc-risks"
            }
        },
        {
            "id": "4592176",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-04T11:16:56-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170407683/image_1170407683.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Still One Of The More Expensive Pharmaceutical Companies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447740",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4592176-johnson-and-johnson-still-one-of-the-more-expensive-pharma-stocks"
            }
        },
        {
            "id": "4592073",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-04T09:07:01-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Huge Opportunity In A Blue-Chip Dividend King",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447671",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4592073-johnson-and-johnson-huge-opportunity-blue-chip-dividend-king"
            }
        },
        {
            "id": "4592128",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-04T07:24:27-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170407683/image_1170407683.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Dividends Not Compensating For Lagging Price Movements",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447914",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4592128-johnson-and-johnson-jnj-dividends-not-compensating-lagging-price-movements"
            }
        },
        {
            "id": "4591940",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-03T11:33:16-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170407683/image_1170407683.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "6 Reasons To Consider Johnson & Johnson Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105843",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447777",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4591940-6-reasons-to-consider-johnson-and-johnson-stock"
            }
        },
        {
            "id": "4591894",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-03T08:57:28-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Don't Run As It's Time To Be Greedy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447648",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4591894-johnson-and-johnson-time-to-be-greedy"
            }
        },
        {
            "id": "4591837",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-03T04:38:06-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181903496/image_1181903496.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Negative Alpha Likely Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106759",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "447705",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4591837-johnson-and-johnson-stock-negative-alpha-likely-ahead"
            }
        },
        {
            "id": "4585535",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-10T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520885672/image_520885672.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "If You Like Johnson & Johnson, You'll Love These Higher-Yielding SWANs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "442192",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4585535-like-johnson-and-johnson-love-higher-yielding-swans"
            }
        },
        {
            "id": "4584413",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-03T15:37:55-05:00",
                "isLockedPro": false,
                "commentCount": 108,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1388548812/image_1388548812.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Kenvue IPO Still Leaves Johnson & Johnson With Most Of The Talc Liabilities - An Update",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "441601",
                            "type": "sentiment"
                        },
                        {
                            "id": "441602",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4584413-kenvue-ipo-still-leaves-johnson-and-johnson-with-most-of-the-talc-liabilities-an-update"
            }
        },
        {
            "id": "4583267",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-01T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 167,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1362707165/image_1362707165.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson At 52-Week Lows: Is It Attractive?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "441060",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4583267-johnson-johnson-stock-at-52-week-lows-is-it-attractive"
            }
        },
        {
            "id": "4578988",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-17T07:50:00-05:00",
                "isLockedPro": false,
                "commentCount": 91,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458549551/image_458549551.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Johnson & Johnson Remain A Top Dividend Aristocrat Stock Going Forward?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "438271",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4578988-will-johnson-and-johnson-remain-a-top-dividend-aristocrat-stock-going-forward"
            }
        },
        {
            "id": "4573999",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-31T16:30:43-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Starting To Look Interesting Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "434993",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4573999-johnson-and-johnson-starting-to-look-interesting-again"
            }
        },
        {
            "id": "4572063",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-24T17:25:30-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Q4 Earnings Highlight Bullish Path In 2023",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104812",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "433433",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4572063-johnson-and-johnson-q4-earnings-highlight-bullish-path-in-2023"
            }
        },
        {
            "id": "4571271",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-20T14:14:58-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1430435347/image_1430435347.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Better 2023 Dividend Stock: AbbVie Or Johnson & Johnson?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "432666",
                            "type": "sentiment"
                        },
                        {
                            "id": "432667",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4571271-better-2023-dividend-stock-abbvie-or-johnson-and-johnson"
            }
        },
        {
            "id": "4569266",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-11T11:45:39-05:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/170616640/image_170616640.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is A Better Dividend Stock Than Roche, Despite A 20% Lower Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "430814",
                            "type": "sentiment"
                        },
                        {
                            "id": "430815",
                            "type": "sentiment"
                        },
                        {
                            "id": "430816",
                            "type": "sentiment"
                        },
                        {
                            "id": "430817",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4569266-johnson-and-johnson-vs-roche-better-dividend-stock"
            }
        },
        {
            "id": "4568406",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-07T00:19:01-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1349255536/image_1349255536.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Kenvue Begins IPO Process As It Seeks To Separate From Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "429950",
                            "type": "sentiment"
                        },
                        {
                            "id": "429865",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4568406-kenvue-begins-ipo-process-seeks-separate-johnson-and-johnson"
            }
        },
        {
            "id": "4567899",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-06T07:15:00-05:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520885672/image_520885672.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "429396",
                            "type": "sentiment"
                        },
                        {
                            "id": "429397",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4567899-johnson-and-johnson-vs-abbvie-the-better-dividend-aristocrat-buy-might-shock-you"
            }
        }
    ]
}